Botulinum Toxin: Concepts and Use in 2008

Advances in Dermatology

Volumn 24, Issue C, 2008, Pages 1-13

  Matarasso, Seth L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

CUTANEOUS PARAMETERS; DRUG CONTRAINDICATION; DRUG EFFECT; ESTHETIC SURGERY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; REVIEW;

BOTULINUM TOXIN TYPE A; COSMETIC TECHNIQUES; HUMANS; INJECTIONS, INTRAMUSCULAR; NEUROMUSCULAR AGENTS; SKIN AGING;

EID: 56349116291     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2008.09.005     Document Type: Review

References (25)

1. Scott AB. Development of bolutinum toxin therapy: dermatol clinics. WB Saunders, Philadelphia. 2004;vol.22:p. 131-3.
2. Erbguth F.J., and Naumann M. Historical aspects of botulinum toxin: Justimus Kerner (1786-1862) and the "sausage poison". Neurology 53 (1999) 1850-1853
3. Carruthers A., and Carruthers J. In: Bolognia J., Jorizzo J.L., Rapini R.V., and Horn T. (Eds). Botulinum toxin dermatology (2003), Mosby, Harcourt Health Sciences, London 2439-2449
4. Botox (botulinum toxin type A) purified neurotoxin complex. [Package insert] (2004), Allergan Inc., Irvine (CA)
5. Lizarralde M., Gutierrez S.A., and Venegas A. Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines. Dermatol Surg 33 (2007) 1328-1333
6. Alam M., Dover J.S., and Arndt K.A. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: A double blind randomized controlled trial. Arch Dermatol 138 (2002) 510-514
7. Borodic G.E., Ferrante R., Pierce B., et al. Histologic assessment of dose related diffusion and muscle fiber response after therapeutic botulinum A toxin injection. Mov Disord 9 (1994) 31-39
8. Lowe N.J. Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives. Dermatol Surg 24 (1998) 1216-1218
9. Durif F. Clinical bioequivalence of the current commercial preparations of botulinum toxin. Eur J Neurol 2 (1995) 17-18
10. Matarasso S.L. Comparison of botulinum toxin types A and B: a bilateral double-blind randomized evaluation in the treatment of the canthal rhytids. Dermatol Surg 29 (2003) 7-13
11. Kadunc B.V., De Almeida A.R.T., Vanti A.A., et al. Botulinum toxin A adjunctive use in manual chemabrasion: controlled long-term study for treatment of upper perioral vertical lines. Dermatol Surg 33 (2007) 1066-1072
12. Solish N., Bertucci V., Dansereau A., et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 33 (2007) 908-992
13. Matarasso S.L. Botulinum toxin for the treatment of facial eccrine chromhidrosis. J Am Acad Dermatol 52 (2005) 89-91
14. Blumentfield A.M., Dodick D.W., and Silberstein S.D. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Dermatol Clin 22 (2004) 167-175
15. Schwartz M., and Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain 18 Suppl 6 (2002) S198-S203
16. Carruthers J., Fagen S., and Matarasso S.L. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 114 (2005) 1-22
17. Carruthers A., Carruthers J., and Samireh S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 31 (2005) 414-422
18. Lowe N.J., Ascher B., Heckmann M., et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 31 (2005) 257-267
19. Matarasso S.L. Decreased tear expression with an abnormal Schirmer's test following botulinum toxin for the treatment of lateral canthal rhytides. Dermatol Surg 28 (2002) 149-152
20. Matarasso S.L., and Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytid. Plast Reconstr Surg 108 (2001) 208-214
21. Matarasso S.L. Complications of botulinum-A exotoxin for hyperfunctional lines. Dermatol Surg 24 (1998) 1249-1254
22. Semchyshyn N., and Sengelmann R.D. Botulinum toxin A treatment of perioral rhytides. Dermatol Surg 29 (2003) 490-495
23. Choe S.W., Cho W.I., Lee C.K., et al. Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg 31 (2005) 502-508
24. Matarasso A., Matarasso S.L., Brandt F.S., et al. Botox-A exotoxin for the management of platysmal bands. Plast Reconstr Surg 103 (1999) 645-652
25. Vadoud-Seyedi J. Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol 43 (2004) 969-971